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ABSTRACT
Single-stranded antisense oligonucleotides (SSOs)
are used to modulate the expression of genes in
animal models and are being investigated as poten-
tial therapeutics. To better understand why syn-
thetic SSOs accumulate in the same intracellular
location as the target RNA, we have isolated a
novel mouse hepatocellular SV40 large T-antigen
carcinoma cell line, MHT that maintains the ability
to efficiently take up SSOs over several years in
culture. Sequence-specific antisense effects are
demonstrated at low nanomolar concentrations.
SSO accumulation into cells is both time and con-
centration dependent. At least two distinct cellular
pathways are responsible for SSO accumulation in
cells: a non-productive pathway resulting in accu-
mulation in lysosomes, and a functional uptake
pathway in which the SSO gains access to the
targeted RNA. We demonstrate that functional
uptake, as defined by a sequence-specific reduction
in target mRNA, is inhibited by brefeldin A and
chloroquine. Functional uptake is blocked by
siRNA inhibitors of the adaptor protein AP2M1, but
not by clathrin or caveolin. Furthermore, we
document that treatment of mice with an AP2M1
siRNA blocks functional uptake into liver tissue.
Functional uptake of SSO appears to be mediated
by a novel clathrin- and caveolin-independent
endocytotic process.
INTRODUCTION
Antisense oligonucleotides (ASOs), designed to selectively
bind to a targeted RNA through Watson–Crick base
pairing, are widely used to modulate gene expression.
ASOs can be designed to modulate RNA function by
multiple mechanisms, with the siRNA and RNase H
mechanisms most commonly exploited (1). In both cases,
the ASO, once bound to the target RNA, promotes deg-
radation of the RNA through endogenous nucleases,
Ago 2 and RNase H, respectively. ASOs designed to
work through the RNase H pathway are single-stranded
oligonucleotides (SSO) that bind to the target RNA, re-
cruiting the cellular enzyme RNase H1, which then cata-
lyzes the cleavage of the targeted RNA (2,3). Chemically
modiﬁed SSOs, delivered systemically, rapidly distribute
out of plasma and are taken up by cells in tissues,
demonstrating robust antisense effects without the need
for formulations (4–9). Though the mechanisms for SSO
distribution from the central compartment into tissues is
poorly understood, recent studies demonstrate at least two
distinct pathways are operant by which SSO accumulate
in liver cells. We refer to these as a non-productive uptake
pathway and productive uptake pathway. The productive
uptake pathway, which delivers SSO to the target RNA
cellular compartment, accounts for <20% of the total
SSO delivered to liver tissue (10). The non-productive
uptake pathway, accounting for the bulk SSO
accumulating in cells is saturable, and the SSO does not
appear to have access to the target RNA.
Most mammalian cells will readily accumulate SSOs, so
the lack of antisense effects cannot be attributed to the
lack of transport into cells (11–14). However, in most
cases, this accumulation in cells does not appear to be
functional without transfection agents (15–17). Primary
keratinocytes and rodent hepatocytes functionally accu-
mulate SSOs when added to the growth media (18,19).
However, functional uptake is lost in primary hepatocytes
after 24–36h in culture, making it difﬁcult to study the
process. It has been reported that incubation of some cells
with high concentrations of SSOs for several days results
in functional uptake (17), but the timing of maximal anti-
sense effects does not correlate with the results observed
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question whether SSO uptake into these cultured cells is
much less efﬁcient than in liver hepatocytes, or conversely
alternate pathway(s) for SSO uptake are being exploited in
these cultured cells compared to pathways being utilized in
liver hepatocytes.
We now describe a mouse hepatocellular carcinoma cell
line that efﬁciently accumulates SSOs in a functional com-
partment and maintains this ability to efﬁciently accumu-
late SSOs for several years. Maximal antisense effects are
achieved within 24h of adding nanomolar concentrations
of SSOs to the cell culture medium, consistent with
maximal antisense effects observed in mouse liver (20).
We have used this cell culture model to investigate the
mechanisms by which SSOs accumulate in liver cells,
demonstrating that both a functional and non-functional
pathway exist. Both SSO uptake pathways appear to be
endosomal with the functional uptake pathway being
clathrin and caveolin independent, but dependent on the
adaptor protein AP2M1. These effects were conﬁrmed in
mouse liver following systemic delivery. Thus, this cell
culture model recapitulates many features of SSO uptake
found in normal mouse liver and allows further character-
ization of the mechanisms of functional SSO accumula-
tion in hepatocytes.
MATERIALS AND METHODS
Cells and reagents
MHT cells were cultured in DMEM supplemented with
10% fetal calf serum, streptomycin (0.1mg/ml), and peni-
cillin (100U/ml). siRNA treatment was performed using
Opti-MEM containing 5mg/ml Lipofectamine 2000 at the
indicated amount of siRNA for 4h at 37 C, as described
previously (21,22). Heparan sulfate, 10K dextran sulfate,
chloroquine, methyl-b-cyclodextrin, Brefeldin A were
purchased from Sigma (St. Louis, MI, USA).
Isolation of MHT cells
Cells were isolated from the liver of a transgenic mouse
( 3-month old) bearing SV40 large T-antigen gene under
the CRP promoter (23). The liver was perfused with
0.5mg/ml collagenase solution (24), and cells were
placed in collagen coated 12-well plates (±collagen)
with either DMEM containing 10% FBS or with
William’s Medium E containing 10% FBS, 10mM
HEPES and 2mM glutamine. Medium was changed
every 3 days. Wells containing growing cells were ex-
panded into 6-well plates. Distinct population of cells
began rapidly growing after  1 month of culture, and
SV40 mRNA expression was monitored in those cells.
Two groups of cells, one from cells grown in Dulbeccos
medium (DM), and one from cells grown in Williams
Medium E (WE) were serially diluted and plated in
96-well collagen coated plates to obtain <1 cell per well.
Cells were identiﬁed that grew under both growth condi-
tions. Four clones from each growth condition (DM and
WE) were selected, further expanded and frozen down.
For the studies described in this article, we used clone 4W.
Preparation of synthetic siRNA and transfection
Synthetic unmodiﬁed siRNAs were purchased from
Dharmacon Research Inc. (Boulder, CO, USA). siRNA
duplexes were formed according to the manufacturer’s in-
structions. The sequences are listed in Supplementary
Table S1. Cells were transfected with siRNAs in Opti-
MEM and 5mg/ml Lipofectamine 2000 (Invitrogen) for
4h. Medium was then changed to complete growth
medium. The siRNA transfection was repeated the
following day.
Oligonucleotide synthesis
Oligonucleotides were phosphorothioate-modiﬁed chimeric
oligonucleotides composed of ﬁve 20-O-(2-methoxy) ethyl
modiﬁcations on both the 50- and 30-ends and 10
oligodeoxynucleotides in the center to support RNase H
activity (Supplementary Table S1) (25). Oligonucleotides
were prepared similar to that described previously (26) on
either an Amersham AKTA 10 or AKTA 100 oligonucleo-
tide synthesizer. Modiﬁcations from the reported proced-
ure include: a decrease in the detritylation time to 1min, as
this step was closely monitored by UV analysis for
complete release of the trityl group; phosphoramidite con-
centration was 0.1M; 4,5-dicyanoimidazole catalyst was
used at 0.7M in the coupling step; 3-picoline was used
instead of pyridine for the sulfurization step, and the time
decreased from 3 to 2min. The oligonucleotides were
puriﬁed by ion-exchange chromatography on an AKTA
Explorer and desalted by reverse phase high performance
liquid chromatography (HPLC). Oligonucleotides were
characterized by ion-pair-HPLC-MS analysis (IP-HPLC-
MS) with an Agilent 1100 MSD system. The purities of
the oligonucleotides were >90%. Fluorescent dyes were
attached to oligonucleotides at the 50-ends using either
ﬂuorescein or Cy3 phosphoramides (Glen Research).
Taqman RT–PCR
Total mRNA was isolated using a QIAGEN RNAeasy kit
(QIAGEN, Valencia, CA, USA). Reduction of target
mRNA expression was determined by real time RT–
PCR (27) using StepOne RT–PCR machines (Applied
Biosystems). The sequences used in the RT–PCR
reaction are listed in Supplementary Table S1. The expres-
sion data was normalized to ribogreen (Invitrogen). Data
are mean values±SDs of three replicates.
Quantitation of SSOs from cell lysates
Following treatment with SR-B1 SSO, cells were try-
spinized, counted, and lysed in 300ml RIPA buffer
(150mM NaCl, 1.0% T X-100, 0.5% sodium deoxy-
cholate, 0.1% SDS and 50mM Tris, pH 8.0). A calibra-
tion curve was prepared in control RIPA cell lysate
ranging from 0.01 to 1mg SR-B1 SSO. Half microgram
of a 27-mer control SSO was added as an internal
standard (IS) to cell lysates and the calibration standards.
SSO was extracted from cell lysates and calibration stand-
ards using a liquid–liquid extraction with phenol/chloro-
form (25,24) followed by solid-phase extraction of the
aqueous phase using phenyl-functionalized silica sorbent
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using a warm-air evaporator and reconstituted in 100ml
4M urea, 25mM EDTA. Samples were analyzed by LC/
MS using a modiﬁcation of a previously described method
(28). BrieFy, separation was accomplished using an 1100
HPLCMS system (Agilent Technologies, Wilmington,
DE, USA) consisting of a quaternary pump, UV
detector, a column oven, an autosampler and a single
quadrupole mass spectrometer. Samples were injected on
an Xbridge OST C18 column (2.1mm 50mm, 2.5mm
particles; Waters, Milford, MA, USA) equipped with a
SecurityGuard C18 guard column (Phenomenex,
Torrance, CA, USA). The columns were maintained at
55 C. Tributylammonium acetate buffer (5mM) and
acetonitrile were used as the mobile phase at a ﬂow rate
of 0.3ml/min. Acetonitrile was increased (gradient) from
20 to 70% over 11min. Mass measurements were made
online using a single quadrupole mass spectrometer and
selected ion monitoring (SIM) of masses corresponding to
the  4 charge state of full-length SR-B1 SSO and  5
charge state of the IS. Peak areas from extracted ion chro-
matograms were determined for SR-B1 SSO and IS and a
trendline established (R
2=0.99) using the calibration
standards, plotting microgram SR-B1 SSO against the
ratio of the peak areas SRB-1 SSO: IS. Total microgram
SSO in cell lysates was determined using the established
trendline and reported as molecules/cell, where molecules/
cell=Avogadro constant * (total microgram SR-B1 SSO/
cell number)/(molecular mass SR-B1 SSO).
Western blotting
Cells were lysed in RIPA lysis buffer. Equal amounts of
protein were resolved on a SDS–PAGE gel and trans-
ferred to membranes. Proteins were detected using
AP2M1 antibodies from Abcam (Cambridge, MA,
USA) and SR-B1 antibodies from Novus (Littleton, CO,
USA). Secondary antibodies (Lincoln, NE, USA) were
conjugated to IR800. Blots were scanned using Odyssey
from LI-COR.
Flow Cytometry
A ﬂuorescein-labeled SSO was added to MHT cells with
or without competitors for 24h. Cells were trypsinized,
resuspended in PBS with 5mM EDTA and analyzed on
FACS Calibur. Transferrin-AF488 (50mg/ml) was added
to cells for 7h before trypsinization and analysis by ﬂow
cytometry.
Immunoﬂuorescence
Cells were grown in glass-bottom dishes (MatTek). Cells
were washed three times with 1  PBS, ﬁxed at room tem-
perature for 15min with 4% formaldehyde and
permeabilized for 5min with 0.05% Saponin in 1  PBS.
Cells were then incubated with 1  PBS with 0.05%
Saponin containing a rabbit polyclonal antibody (6653)
that recognizes phosphorothioate backbone containing
oligonucleotides (1:200) or a rat anti-mouse LAMP1
antibody (1:1000, clone 1D4B, BD, Bioscience). After
three washes (5min each) with 1  PBS, cells were incu-
bated for 1h with PBS containing secondary antibodies
against rabbit and mouse. After three washes, slides were
mounted with Dapi Fluoromount G (Southern Biotech).
Cells were imaged with a confocal microscope (Olympus,
Fluoview 1000) and images were processed using software
FV10-ASW 2.1. In some experiments the localization of
the ﬂuorescent labeled SSO was determined in unﬁxed
cells using the confocal Olympus Fluoview 1000 or the
Leica DM4000 B upright microscope.
siRNA formulation into LNP
Stock solutions of lipidoid 98N12-5 (1)·4HCl, cholesterol
and mPEG2000-DMG MW 2660 (synthesized by Alnylam)
were prepared in ethanol and mixed to yield a molar ratio
of 42:48:10 (29). siRNA was incorporated in the nano-
particles at 1:7.5 (wt:wt) siRNA:total lipids. Resulting
particles had a mean particle diameter of  50nm and
siRNA entrapment efﬁciency >95%.
In vivo mouse dosing
Balb/C male mice were purchased from Charles River
Laboratories (Wilmington, MA, USA). siRNA were
formulated with LNP01 and housed ﬁve per cage in box
cages. Mice were maintained on feed and water ad libitum.
All animal studies were conducted utilizing protocols and
methods approved by the Institutional Animal Care and
Use Committee (IACUC) and carried out in accordance
with the Guide for the Care and Use of Laboratory
Animals adopted and promulgated by the US National
Institutes of Health. siRNA were formulated with
LNP01. On day 1 and 7, 10mg/kg AP2M1 and luciferase
siRNA or PBS were administered with intravenous (i.v.)
injection (tail vein). On day 14, 20mg/kg SR-B1 SSO (ISIS
353382) was administered as a subcutaneous bolus injec-
tion. On day 17, mice were sacriﬁced. Liver were collected
at sacriﬁce, 72h after dosing was completed. A portion of
each liver was homogenized in guanidine isothiocyanate
buffer for mRNA extraction and RT–PCR analysis. The
remaining liver was ﬂash frozen and stored at  70 C until
assayed for protein reduction.
RESULTS
A mouse hepatocellular carcinoma cell line demonstrates
speciﬁc antisense effects by free uptake
A stable mouse cell line, called MHT, was isolated from a
hepatocellular carcinoma tumor which developed in a
transgenic mouse expressing SV40 large T-antigen under
the CRP promoter (23). To characterize the uptake of
SSO, MHT cells were treated with 20-MOE modiﬁed
SSOs that were designed to work through RNase H1
(Supplementary Table S1) targeting the nuclear retained
non-coding RNA, Malat1 (30), scavenger receptor B1
(SR-B1) and phosphatase and tensin homolog (PTEN)
(5) in the presence or absence of a cationic lipid. The
IC50 values for the Malat1, SR-B1 and PTEN SSO were
1, 3 and 21nM, respectively, using Lipofectin reagent
(Figure 1A). In the absence of cationic lipid, each of the
SSOs produced a dose-dependent reduction of their re-
spective targets with IC50 values for the Malat1, SR-B1
Nucleic Acids Research, 2011,Vol.39, No. 11 4797and PTEN SSO of 0.6, 1 and 8000nM, respectively, when
incubated for 48h (Figure 1B). The cells have maintained
their ability to efﬁciently accumulate SSO in a functional
compartment for prolonged periods of time in culture,
although we do ﬁnd that over time in culture there is
some loss in sensitivity. Therefore, we thaw an early
passage of the cells after 20–25 passages. Mice were
treated with a single injection of all three SSOs and
effects on targeted gene expression in liver were
determined (Figure 1C). The Malat1 and the SR-B1
SSOs exhibited an ED50 of 1.7 and 10mg/kg, respectively,
while the ED50 for the PTEN SSO was  52mg/kg. The
rank-order potency for the three different SSOs was the
same by cationic lipid-mediated transfection, free uptake,
or systemic administration to mice. The target reduction
was sequence-speciﬁc and had no effect on the transcripts
of the other two genes (Supplementary Figure S1).
The maximal effects of 1mM SR-B1 SSO on SR-B1 ex-
pression occurred  30h after adding the SSO to the media
(Figure 2A). Maximal effects of lower concentrations
of SSO occurred at 48–72h (data not shown). A control
SSO failed to modulate SR-B1 expression, further demon-
strating that the reduction in SR-B1 expression was
sequence speciﬁc (Figure 2A). Attachment of the ﬂuores-
cein dye to the 50-o r3 0-end of a SSO did not affect
potency for reduction of the target RNA (data not
shown), suggesting that the ﬂuorescent dye did not inter-
fere with functional uptake, hybridization to the target
mRNA or RNase H cleavage. Using a ﬂuorescein
labeled SSO to quantitate cellular uptake, we demonstrate
that cellular uptake was time-dependent and did not
saturate over 70h (Figure 2B). Similar to unlabeled
SSO, the ﬂuorescein-labeled SR-B1 SSO produced max-
imal effects on SR-B1 expression between 24 and 48h
after addition to the cells. We used mass spectrometry to
more precisely quantitate the amount of unlabeled SSO in
cells to correlate the number of SSO molecules in the cell
with target mRNA reduction. Approximately 0.3 10
6
SSO molecules/cell were required to reduce SR-B1
mRNA by 50%, which was achieved by exposing the
cells to 7nM SR-B1 SSO (Figure 2C).
To characterize the kinetics of cell association, we incu-
bated the MHT cells for 15min to 2h in the presence
of 6nM to 20mM SR-B1 SSO to allow the SSO to bind
to the cell surface and then washed the cells to remove free
SSO and incubated for an additional 24h. The potency
was decreased compared to cells that were continually
exposed to SSO for 24h (Figure 2D). However, incuba-
tion of cells with SSO for as short as 15min resulted in a
concentration dependent reduction in SR-B1 expression,
suggesting that SSOs quickly associated with cells.
Continued exposure of SSOs to cells up to 2h resulted
in only a modest increase in SR-B1 mRNA reduction
compared to 15min incubation (Figure 2D). These
results suggest that the SSOs initially bind to the cell
surface and then are internalized into the functional
pool. Pretreatment of the cells with trypsin dramatically
reduced the speciﬁc antisense effects, suggesting that the
SSOs interact with proteins expressed on the surface of
MHT cells (Supplementary Figure S2).
Functional uptake of SSO in MHT cells is
chemistry dependent
Although we were unable to demonstrate saturation of
cellular uptake of oligonucleotide at concentrations up
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Figure 1. SSOs decrease SR-B1, PTEN and Malat1 expression in MHT
cells and mouse liver. (A) MHT cells were transfected with SSOs using
Lipofectin reagent for 4h. Approximately 20h after transfection, cells
were harvested and the respective mRNA measured by real time
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4798 Nucleic Acids Research, 2011,Vol.39, No. 11to 10mM, we reasoned that binding to the cell surface
should be a saturable event, therefore we used a control
SSO to compete for cell uptake into the functional
pool (Figure 3A). The antisense effects of the SR-B1
SSO were attenuated in the presence of increasing concen-
trations of a control SSO (Figure 3A). The control
SSO also decreased the amount of ﬂuorescently labeled
SSO associated with cells consistent with the loss in
pharmacological activity (Supplementary Figure S3).
SSOs have three major chemical pharmacophores: the
heterocycle base, the pentose sugar and the phosphate
internucleosidic linkage. To determine the chemical struc-
tures recognized by this functional uptake pathway,
we used different chemically modiﬁed oligonucleotides
as competitors for functional uptake. The data suggest
that SSOs containing more DNA were better competitors
for functional uptake. As an example, maintaining the
same oligonucleotide length and varying the amount
of 20-MOE and DNA modiﬁcation demonstrates that
increasing the 20-MOE content from 4 to 10nt and con-
versely decreasing the amount of DNA in the SSO resulted
in decreased competition for functional uptake
(Figure 3B). Similarly, if the length of the SSO was
varied by increasing the DNA gap size and maintaining
two 20-MOEs at each end, there was a good correlation
between DNA content and ability to compete (Figure 3C
and D). This was true for MHT cells and primary hepato-
cytes. Keeping the DNA gap constant, but increasing the
length of the SSO by increasing the 20-MOE wings,
resulted in a similar degree of competition for the different
length SSOs (Figure 3E), further demonstrating that DNA
content is more important than length.
An abasic phosphorothioate deoxyribose oligomer
(N=20) failed to compete for antisense activity suggest-
ing that the hydrophobic bases may contribute to cell
uptake into the functional pool (data not shown). Also,
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RNAs in which the bases are base paired do not com-
pete for uptake (data not shown). We investigated the
ability of other polyanions to compete for functional
cell uptake. Dextran sulfate at high concentrations attenu-
ates the effect of the SSO, while low concentrations
of dextran sulfate either had no effect or slightly
enhanced the effect of the SSO (Figure 4A). Dextran
sulfate decreased the amount of SSO associated with
cells in a concentration dependent manner (Figure 4B).
Suramin also weakly inhibited functional cell uptake
(Supplementary Figure S4A), and heparan sulfate in-
hibited functional cell uptake only at high concentrations
(Supplementary Figure S4B). These results demonstrate
that functional uptake into MHT cells is not just due to
polyanions interacting with membrane proteins, but
appears to be also due to recognition of both the base
and sugar.
The bulk of SSOs accumulating in MHT cells localizes in
vesicular structures
The localization of a ﬂuorescein-labeled SSO was
determined in the presence or absence of cationic lipid.
Similar to previous results (15), we found that the SSO
primarly localized in the nucleus when delivered into the
cells with cationic lipids (Figure 5A). In the absence of
cationic lipid, the highest concentration of SSO was
found in punctuate peri-nuclear structures (Figure 5A–
D). The same SSO distribution was seen in ﬁxed and
live cells (data not shown). We used antibodies to the
lysosomal membrane protein 1 (LAMP1) to determine if
the SSO co-localized in lysosomal structures. Two hours
after adding the ﬂuorescein-conjugated SSO to cells, SSOs
localized to punctuate structures in the cytoplasm but did
not co-localize with lysosomes (Figure 5B). However, after
24h most of the ﬂuorescent SSO co-localized with lyso-
somes (Figure 5C), suggesting that SSO accumulation in
lysosomes is a slow process in these cells. Unconjugated
SSO also localized in punctuate peri-nuclear structures as
demonstrated using a polyclonal antibody that recognizes
phosphorothioate modiﬁed SSO. The localization of the
unlabeled SSO was similar to SSO labeled with ﬂuorescein
or Cy3 (Figure 5D).
Functional SSO uptake in MHT cells is an endocytotic
process
We used pharmacological inhibitors of various endocytot-
ic processes to further deﬁne the pathways which SSO
accumulate in the functional compartment of cells.
Chloroquine, an inhibitor of lysosome acidiﬁcation, and
Brefeldin A (BFA), a lactone antibiotic that blocks retro-
grade protein transport from the Golgi apparatus to the
endoplasmic reticulum (31,32), both antagonized the anti-
sense effects of the SR-B1 SSO (Supplementary Figure
S5A and B). Although choroquine was very effective in
blocking the antisense effects of the SSO, it had no effect
on cellular uptake and, in fact, increased the total SSO in
cells (data not shown), suggesting that choroquine did not
block cell uptake but affected intracellular dynamics of
the SSO. BFA slightly inhibited SSO uptake (data not
shown). Incubation of MHT cells with methyl-
b-cyclodextrin (MbCD), which depletes cells of cholesterol
and 1mg/ml lovostatin (33,34), modestly inhibited the
antisense activity of the SR-B1 SSO (Supplementary
Figure S5C). Finally, dynasore, a small molecule
dynamin inhibitor, and a dynamin siRNA both failed to
inhibit functional uptake (Supplementary Figure S6). In
these experiments, dynamin mRNA levels were reduced by
80% compared to control siRNA-treated cells (data not
shown).
To further deﬁne the pathways involved we chose to
inhibit the expression of speciﬁc genes using siRNA. We
chose to use siRNA for these experiments as they exploit a
different molecular mechanism than SSOs and therefore
should not result in competition for RNase H or other
components required for the SSOs used in these studies,
potentially complicating interpretation of the data. We
screened a mouse siRNA library targeting membrane
trafﬁcking proteins for effects on antisense activity of
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Figure 4. Dextran sulfate competes for bulk uptake and functional
SSO uptake. Increasing doses of SR-B1 SSO was added to complete
medium with or without the indicated concentrations of dextran sulfate
for 24h. (A) High concentrations (10mM) dextran sulfate decrease the
pharmacological effects of the SR-B1 SSO while 1mM dextran sulfate
does not inhibit the pharmacological effects of the SR-B1 SSO.
(B) Dextran sulfate inhibits SSO accumulation in MHT cells. MHT
cells were incubated with 50nM of ﬂuorescein labeled SR-B1 SSO in
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At the end of the incubation period cells were collected and the amount
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Figure 5. Localization of ﬂuorescently labeled SSO in MHT cells. (A) Fluorescein labeled SSO was transfected into MHT cells using lipofectin
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structures and visualized using confocal microscopy. Nuclei of the cells were counterstained with DAPI. (C) MHT cells were incubated with 100nM
ﬂuorescein labeled SR-B1 SSO (green) for 24h and cells were ﬁxed and permeabilized. Cells were stained with a LAMP1 antibody (red) to label
lysosomal structures and visualized using confocal microscopy. Nuclei of the cells were counterstained with DAPI (blue). (D) MHT cells were
incubated with 100nM unlabeled SR-B1 SSO (top row), ﬂuorescein conjugated SR-B1 SSO or Cy3 labeled SR-B1 SSO for 24h. At the end of the
incubation period, cells were ﬁxed and stained for LAMP1 using an unlabeled LAMP1 monoclonal antibody, followed by either a ﬂuorescein (top
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antibody, was detected using a rabbit polyclonal antibody that recognizes the phosphorothioate backbone present in the SSO followed by a Texas
red goat anti-rabbit antibody.
4802 Nucleic Acids Research, 2011,Vol.39, No. 11the SR-B1 SSO (35). As a positive control we demo-
nstrated that RNAse H1 siRNAs (Figure 6A) decreased
the activity of the SSOs, indicating that they work through
an RNAse H1 dependent mechanism. In this experiment
the RNase H siRNAs reduce the amount of RNase H
mRNA by 75%. The strongest and most reproducible
hit for inhibiting the effects of the SR-B1 SSO was the
adaptor protein AP2M1. Inhibition of AP2M1 with
either a pool of four siRNAs or individual siRNAs in
the pool attenuated the antisense effects of SR-B1 SSO
(Figure 6B). Treatment with the AP2M1 siRNA pool
resulted in an 80% inhibition of AP2M1 mRNA levels
(Figure 6C). Inhibition of AP2M1 expression decreased
ﬂuorescein labeled SSO uptake by 50% (Supplementary
Figure S7A). AP2M1 is an adaptor protein that recog-
nizes a peptide sequence on the cytoplasmic face of cell
membrane proteins linking the cell membrane cargo to
clathrin (36,37). Surprisingly, inhibition of clathrin ex-
pression using siRNAs (80% inhibition, data not shown)
had no effect on the SSO activity (Figure 6A and
Supplementary Figure 6B), but did decrease the uptake
of ﬂuorescently labeled transferrin uptake in MHT cells,
as did the AP2M1 siRNA and chlorpromazine
(Figure 6D). These results demonstrate that functional
uptake of SSO into MHT cells is AP2M1-dependent,
but clathrin independent. Inhibition of caveolin expression
also had no effect on functional SSO uptake (data not
shown).
We extended these observations to mouse liver. AP2M1
or luciferase siRNAs were administered to mice on day 1
and 7 using a lipidoid nanoparticle (LNP) formula-
tion (38). An unformulated SSO targeting SR-B1 was
B A
D C
0
25
50
75
100
125
1 10 100 1000 10000
SR-B1 ASO [nM] 
S
R
-
B
1
 
m
R
N
A
 
(
%
 
c
o
n
t
r
o
l
)
SR-B1 ASO + 25 nM AP2M1 siRNA
SR-B1 ASO + 25 nM ctr siRNA
SR-B1 ASO
0
no transferrin control clathrin AP2M1 chlorpromazine
40
20
60
80
100
120
140
siRNA
0
25
50
75
100
125
150
1 10 100 1000 10000
SR-B1 ASO [nM] 
A
P
2
M
1
 
m
R
N
A
 
(
%
 
c
o
n
t
r
o
l
)
SR-B1 ASO + 25 nM AP2M1 siRNA
SR-B1 ASO + 25 nM ctr siRNA
SR-B1 ASO
0
20
40
60
80
100
120
control AP2M1 clathrin  RNAse  H1 
S
R
-
B
1
 
m
R
N
A
 
(
%
 
c
o
n
t
r
o
l
)
siRNA 
Figure 6. SSO mediated functional uptake in MHT cells is AP2M1 dependent and clathrin independent. (A) MHT cells were treated with 25nM
control, AP2M1, clathrin or RNAse H1 siRNAs 2 days prior to adding 80nM SR-B1 SSO. Cells were incubated an additional 24h with the SR-B1
SSO and SR-B1 mRNA levels determined by qRT–PCR. SR-B1 mRNA reduction in AP2M1 siRNA-treated cells are inhibited compared to control
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concentrations of the SR-B1 SSO were added to the cells in complete medium for an additional 24h. Total cell RNA was isolated and SR-B1 (B) and
AP2M1 (C) mRNAs were measured using qRT-PCR. (D) MHT cells were treated with 25nM clathrin, AP2M1 or control siRNAs for 48h, after
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Nucleic Acids Research, 2011,Vol.39, No. 11 4803injected subcutaneously on day 14 and mice were
sacriﬁced on day 17. As observed in MHT cells, inhibition
of AP2M1 in mouse liver blunted the antisense effects of
the SR-BI SSO while the luciferase siRNA had no effect
on SR-B1 reduction (Figure 7A). The AP2M1 siRNA
resulted in 80% reduction of mouse AP2M1 mRNA
(Figure 7B). Inhibition of AP2M1 also inhibited SR-B1
protein reduction by the SR-B1 SSO (Figure 7C). The
siRNA reduced AP2M1 protein by 60% (Figure 7D).
DISCUSSION
ASOs show promise as therapeutic agents, while also
being widely used to functionalize gene targets (27). The
chemistry of SSO drugs has evolved to improve potency,
pharmacokinetic properties and safety. Although many
cell types will accumulate SSOs in a functional pool, it is
not well understood how polyanionic SSOs gain access to
the cytoplasmic and/or nuclear compartments of the cell
where they can bind to the target RNA. Understanding
how SSOs trafﬁc in cells can lead to more efﬁcient design
of SSOs and better dosing paradigms.
Unfortunately, there has been a paradox in how SSOs
behave in cell culture and how they behave in the intact
organism. For most cultured cells, transfection agents are
required to produce robust antisense effects. In contrast,
systemic dosing of SSOs results in antisense effects in a
broad range of peripheral tissues and administration into
the CSF provides access to a variety of neuronal cell types
(21,39–43). We report the isolation of a cell line, MHT,
from livers of a transgenic mouse expressing SV40 large
T-antigen that maintain functional SSO uptake. Cellular
uptake pathways appear to be similar in this cell line
compared to the mechanisms of uptake in mice,
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4804 Nucleic Acids Research, 2011,Vol.39, No. 11supporting their use to gain a better understanding of SSO
trafﬁcking in cells. SSOs reduce their target RNAs at
nanomolar concentrations, effects are observed within
24h of administration and are similar to in vivo observa-
tions (10). The bulk SSO taken up by the cells is eventually
found in lysosomes.
The uptake of SSO into mouse liver is time and concen-
tration dependent as was the ﬁnding in MHT cells
(10,20,44). We demonstrate that the bulk of SSO which
accumulates in MHT cells does not appear to be in the
productive uptake pathway as evidenced by the competi-
tion studies with dextran sulfate in which we can reduce
the total amount of SSO in cells by 60% and not antisense
activity. Non-productive uptake pathways seem to exist in
animal tissues as well. Delivery of SSOs with slow infusion
led to increased SSO concentration in liver compared to
i.v. bolus administration that was expected (10).
Unexpectedly, however, an increase in liver drug concen-
tration due to slower infusion did not confer improved
pharmacodynamics, perhaps suggesting that the low
plasma concentration favored an uptake pathway that
is, in part, a non-productive pathway. This was further
supported by studies using a control SSO as a competitor,
in which the competitor decreased total SSO concentra-
tion in liver by 80%, yet paradoxically increased
pharmacodynamic effects (10).
Our results suggest that functional uptake is a vesicular
uptake process, since it is blocked by choroquine,
brefeldin A and the inhibitor of adaptor protein subunit
AP2M1. Interestingly, functional uptake does not appear
to be mediated by clathrin or caveolin, but is dependent
on the adaptor protein AP2M1. Most endocytotic
pathways described in the literature that are AP2 depend-
ent are also clathrin dependent. In general, clathrin-
independent pathways are described but are poorly
characterized. The minor group human rhinoviruses
bind low-density lipoprotein receptors and are internalized
by classical clathrin-dependent endocytosis (45,46).
However, the virus can enter cells through a clathrin-,
caveolin- and ﬂotillin-independent pathway (46,47).
Recently, functional free uptake of a 16-mer LNA
gapmer SSO targeting bcl-2 was reported in several cell
lines (17). Cells were plated at low density and exposed to
high concentrations of SSOs over days to produce the
antisense effects. Contrary to our observations, the
authors report that LNA SSO is taken up much slower
and maximal target reduction does not occur until 5 days
after SSO exposure. They localized the LNA SSOs in
P-bodies, while we failed to observe MOE SSOs in
P-bodies (Supplementary Figure S8). The LNA modiﬁed
SSO used in the study were designed to work through an
RNase H dependent mechanism. As the authors failed to
show that the LNA modiﬁed SSOs used in their study
worked through a RISC dependent or RNase H mechan-
ism, it is not clear if the localization to P-bodies is func-
tional. We looked at the effect of LNA SSOs in the
competition assay and we found that LNA compete in a
similar manner as MOE-gapmers. It is possible that the
16-mer LNA gapmers could have different uptake abilities
than the 20-mer MOE-gapmer. However, based upon our
preliminary results in MHT cells using LNA and related
structures we do not believe that to be the case. More
likely scenarios are that the human cell lines used to
study uptake of ASOs by Stein et al. (17) retain a
similar functional uptake pathway as the MHT cells but
it is much less efﬁcient. Alternatively, the MHT cells used
in our study have a distinct SSO uptake pathway not
found in the cells used by Stein et al. (17). Additional
studies are needed to determine if these are distinct
pathways for functional uptake of SSOs.
We have identiﬁed AP2M1 as an important adaptor
protein for free uptake of SSOs and subsequent target
reduction in MHT cells and in mouse liver. These results
help validate MHT cells as a cell culture model to study
SSO uptake and trafﬁcking. We have tested other cells like
mouse embryo ﬁbroblasts and H2.35 liver cells where in-
hibition of AP2M1 inhibited SSO mediated target reduc-
tion. This shows that AP2M1 plays a similar role in cells
other than MHT cells. Additional studies are needed to
identify the cell surface proteins that the SSOs interact
with, how the adaptor protein facilitates SSO internaliza-
tion and how SSO escape endosomal vesicles. However,
these studies are an important ﬁrst step in characterizing
how SSOs gain access to target RNAs in the nucleus and/
or cytoplasm of cells. A better understanding of how SSOs
enter cells and how they reach their target RNA will aid in
the design of more potent SSO drugs and more speciﬁc
targeting.
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